☰

Justin G. Meyerowitz, Ph.D. - Publications

Affiliations: 
2014 Chemistry and Chemical Biology University of California, San Francisco, San Francisco, CA 
Area:
signal transduction pathways in cells and whole organisms
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Burnett GL, Yang YC, Aggen JB, Pitzen J, Gliedt MK, Semko CM, Marquez A, Evans JW, Wang G, Won WS, Tomlinson ACA, Kiss G, Tzitzilonis C, Thottumkara AP, Cregg J, ... ... Meyerowitz JG, et al. Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. Journal of Medicinal Chemistry. PMID 36533617 DOI: 10.1021/acs.jmedchem.2c01658  0.48
2016 Olow A, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss WA, Resnick AC, Waanders AJ, Stalpers LJ, Berger MS, Gupta N, James CD, Petritsch CK, Haas-Kogan DA. BRAF status in personalizing treatment approaches for pediatric gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27217440 DOI: 10.1158/1078-0432.Ccr-15-1101  0.594
2016 Lee JK, Phillips JW, Smith BA, Park JW, Stoyanova T, McCaffrey EF, Baertsch R, Sokolov A, Meyerowitz JG, Mathis C, Cheng D, Stuart JM, Shokat KM, Gustafson WC, Huang J, et al. N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial Cells. Cancer Cell. 29: 536-47. PMID 27050099 DOI: 10.1016/J.Ccell.2016.03.001  0.687
2015 Meyerowitz JG, Weiss WA, Gustafson WC. A new "angle" on kinase inhibitor design: Prioritizing amphosteric activity above kinase inhibition. Molecular & Cellular Oncology. 2: e975641. PMID 27308435 DOI: 10.4161/23723556.2014.975641  0.788
2015 Olow AK, Mueller S, Yang X, Hashizume R, Meyerowitz J, Weiss W, Resnick AC, Waanders AJ, Berger MS, Gupta N, James CD, Haas-Kogan DA. TR-08 * TARGETED COMBINATORIAL APPROACH FOR TREATMENT OF PEDIATRIC LOW GRADE GLIOMAS IN THE CONTEXT OF BRAFV600E AND KIAA1549:BRAF MUTATIONS Neuro-Oncology. 17: iii38-iii38. DOI: 10.1093/Neuonc/Nov061.153  0.608
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell. 26: 414-27. PMID 25175806 DOI: 10.1016/J.Ccr.2014.07.015  0.695
2014 Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG, Weiss WA. The prenatal origins of cancer. Nature Reviews. Cancer. 14: 277-89. PMID 24599217 DOI: 10.1038/Nrc3679  0.565
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Charron E, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA. Abstract PR08: Drugging MYCN protein stability through an allosteric transition in Aurora kinase A Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr08  0.783
2014 Meyerowitz JG, Gustafson WC, Nekritz E, Swartling F, Shokat KM, Ruggero D, Weiss WA. Abstract B78: Targeting the translational apparatus in MYCN-driven medulloblastoma Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-B78  0.739
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Charron EA, Chanthery Y, Simonds E, Matthay K, Hertz N, Shokat K, Weiss WA. Abstract 2688: Drugging MYCN through an allosteric transition in Aurora A kinase Cancer Research. 74: 2688-2688. DOI: 10.1158/1538-7445.Am2014-2688  0.65
Show low-probability matches.